日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial

口服ALDH2抑制剂ANS-6637对酒精使用障碍成人患者的线索诱发渴求、安全性和酒精摄入量的初步影响:一项概念验证性随机人体实验室试验

O'Malley, Stephanie S; Miranda, Robert Jr; Book, Sarah W; Chun, Thomas H; Liss, Thomas; Malcolm, Robert J; Muvvala, Srinivas B; Padovano, Hayley Treloar; Schacht, Joseph P; Blackburn, Brent; Diamond, Ivan; Ransom, Janet; Ryan, Megan L; Falk, Daniel E; Litten, Raye Z

The GABA-B receptor agonist baclofen helps patients with alcohol use disorder: why these findings matter

GABA-B受体激动剂巴氯芬有助于治疗酒精使用障碍患者:这些发现为何重要

Leggio, Lorenzo; Litten, Raye Z

Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline

酒精线索反应性对寻求治疗的酒精使用障碍患者后续治疗结果的影响:一项伐尼克兰多中心随机、双盲、安慰剂对照临床试验

Miranda, Robert Jr; O'Malley, Stephanie S; Treloar Padovano, Hayley; Wu, Ran; Falk, Daniel E; Ryan, Megan L; Fertig, Joanne B; Chun, Thomas H; Muvvala, Srinivas B; Litten, Raye Z

Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice

改善酒精使用障碍药物研发并促进其在临床实践中常规使用的五个优先领域

Litten, Raye Z; Falk, Daniel E; Ryan, Megan L; Fertig, Joanne; Leggio, Lorenzo

Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials

以饮酒风险水平作为酒精药物治疗试验结果的评估:3项随机临床试验的二次分析

Falk, Daniel E; O'Malley, Stephanie S; Witkiewitz, Katie; Anton, Raymond F; Litten, Raye Z; Slater, Megan; Kranzler, Henry R; Mann, Karl F; Hasin, Deborah S; Johnson, Bankole; Meulien, Didier; Ryan, Megan; Fertig, Joanne

Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety

加巴喷丁依那卡比缓释片治疗酒精使用障碍:一项评估疗效和安全性的随机、双盲、安慰剂对照、多中心试验

Falk, Daniel E; Ryan, Megan L; Fertig, Joanne B; Devine, Eric G; Cruz, Ricardo; Brown, E Sherwood; Burns, Heather; Salloum, Ihsan M; Newport, D Jeffrey; Mendelson, John; Galloway, Gantt; Kampman, Kyle; Brooks, Catherine; Green, Alan I; Brunette, Mary F; Rosenthal, Richard N; Dunn, Kelly E; Strain, Eric C; Ray, Lara; Shoptaw, Steven; Ait-Daoud Tiouririne, Nassima; Gunderson, Erik W; Ransom, Janet; Scott, Charles; Leggio, Lorenzo; Caras, Steven; Mason, Barbara J; Litten, Raye Z

Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder

饮酒风险水平降低与酒精使用障碍患者的身体健康和生活质量改善相关

Witkiewitz, Katie; Kranzler, Henry R; Hallgren, Kevin A; O'Malley, Stephanie S; Falk, Daniel E; Litten, Raye Z; Hasin, Deborah S; Mann, Karl F; Anton, Raymond F

Addictions Neuroclinical Assessment: A reverse translational approach

成瘾神经临床评估:一种反向转化方法

Kwako, Laura E; Momenan, Reza; Grodin, Erica N; Litten, Raye Z; Koob, George F; Goldman, David

Posttreatment Low-Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders: A 9-Year Follow-Up

治疗后低风险饮酒作为预测酒精使用障碍患者未来饮酒和问题结局的指标:一项为期9年的随访研究

Kline-Simon, Andrea H; Litten, Raye Z; Weisner, Constance M; Falk, Daniel E

Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study

COMBINE研究中重度饮酒者重度饮酒天数和饮酒量减少的时间稳定性

Witkiewitz, Katie; Wilson, Adam D; Pearson, Matthew R; Hallgren, Kevin A; Falk, Daniel E; Litten, Raye Z; Kranzler, Henry R; Mann, Karl F; Hasin, Deborah S; O'Malley, Stephanie S; Anton, Raymond F